Table 1

Cause of death within the first 12 months following trial entry

AllMEPEXCYCAZAREMCYCLOPSNORAM
All causes (% of patients in the respective group)56 (10.7)33 (25)7 (4.5)14 (9.3)2 (2.2)
Infection (%)28 (50)17 (51) [1*]4 (57) [3*]6 (66) [0*]1 (50) [0*]
Active vasculitis (%)8 (14)5 (15)0 (0)2 (14)1 (50)
Cardio/cerebrovascular disease (%)7 (13)4 (16)2 (29)1 (7)0 (0)
GI bleed/duodenal ulcer (%)3 (5)2 (6)1 (14)0 (0)0 (0)
PE or complication of anticoagulation (%)3† (5)1 (3)0 (0)2 (14)0 (0)
Malignancy (%)1 (2)0 (0)0 (0)1 (7)0 (0)
Pulmonary fibrosis (%)2 (4)1 (3)0 (0)1 (7)0 (0)
Other (%)4 (7)3 (9)0 (0)1 (7)0 (0)

  • ↵* Active vasculitis at time of death also.

  • ↵† Including one death due to gastrointestinal (GI) bleeding in the context of warfarin therapy.

  • PE, pulmonary embolism.